Pemvidutide: a GLP-1 + glucagon dual drug in trials
Pemvidutide is an experimental weight-loss shot that targets two body signals at once. It is still in trials, not approved, and not sold anywhere, including India.
You may have heard friends talk about a 'new weight-loss shot.' One name popping up in news is pemvidutide. It sounds exciting because it does two things at once. But here is the honest truth first: pemvidutide is still being tested. No doctor can prescribe it yet. It is not in any shop, not online, and not in India. This short read tells you what it is, what the trials found, and why you should wait.
What pemvidutide is, in plain words
Pemvidutide is a lab-made peptide (a tiny protein bit) given as a once-weekly shot under the skin. The company making it is called Altimmune. It is called a 'dual agonist.' That means it switches on two body signals at the same time. One signal is GLP-1, the same one medicines like semaglutide use to cut appetite and make you feel full. The other signal is glucagon, which can nudge the body to burn more energy and fat. The idea is simple: eat less AND burn a bit more. The company itself calls it 'a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist.' The key word is investigational, meaning still under study.
Two pemvidutide trials you may hear about
Pemvidutide is already a better weight-loss medicine you can get now.
mostly falseMostly false. The number is real, but the 'you can get it now' part is wrong. In the MOMENTUM phase 2 trial, after 48 weeks the highest dose (2.4 mg) gave an average weight loss of 15.6%, versus 2.2% for placebo. That is a strong trial result for an experimental drug. But it is only phase 2 data, in 391 people, from the company's own report. Pemvidutide is not approved, not prescribed, and not available. Calling it a 'medicine you can get' is false. It is a study drug, years from any approval decision.
The fatty-liver bonus that makes it interesting
Here is why doctors are watching pemvidutide, not just for weight. The same drug also helped people with MASH, a fatty liver disease linked to obesity. In the IMPACT phase 2b trial, MASH resolved (without worsening liver scarring) in 58% of the 1.2 mg group and 52% of the 1.8 mg group, versus 20% on placebo. That is a meaningful result for a liver disease that has few treatments. Still, this is early data, and the trial's other goal (liver scarring improving at 24 weeks) was not met. More and longer trials are planned. So the liver promise is real but unproven for now.
What you should actually do right now
The bottom line
Pemvidutide is a promising study drug, not a medicine you can get. It targets GLP-1 and glucagon at once, and early trials show strong weight loss (15.6% at 48 weeks) and helpful fatty-liver effects. But it is still experimental, years from approval, and not available in India or anywhere else. Do not buy it. Talk to your doctor about options that are approved today.